Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neuropathology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44363   clinical trials with a EudraCT protocol, of which   7387   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Neuropathology. Displaying page 1 of 1.
    EudraCT Number: 2009-011252-22 Sponsor Protocol Number: CeTeG Start Date*: 2010-07-09
    Sponsor Name:Medical Faculty, University of Bonn
    Full Title: Phase III trial of CCNU/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT-methylated glioblastoma patients (CeTeG)
    Medical condition: Newly diagnosed patients with glioblastoma harbouring a methylated MGMT promoter
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005786-60 Sponsor Protocol Number: FET-PET-2010 Start Date*: Information not available in EudraCT
    Sponsor Name:Charité Universitaetsmedizin Berlin
    Full Title: A prospective, multicentre trial on the value of 18F-FET PET in the post-therapeutic evaluation of childhood brain tumours
    Medical condition: Children and adolescents with a primary brain tumour after first line therapy
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000304-14 Sponsor Protocol Number: GlioVax Start Date*: 2018-03-06
    Sponsor Name:Heinrich-Heine-University Düsseldorf
    Full Title: Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma
    Medical condition: newly diagnosed glioblastoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002185-23 Sponsor Protocol Number: DIPG Start Date*: 2015-07-29
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Phase 2 open label randomized study of radiotherapy, concomitant nimotuzumab and vinorelbine and re-irradiation at relapse versus radiotherapy and multiple elective radiotherapy courses with concom...
    Medical condition: diffuse intrinsic pontine glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015036-15 Sponsor Protocol Number: AVIRMA Start Date*: 2010-01-21
    Sponsor Name:Medizinische Universität Innsbruck - Universitätsklinik für Neurologie
    Full Title: Avastin / Irinotecan in patients with recurrent or progressive malignant glioma An academic prospective single-arm phase II clinical trial for evaluation of advanced functional neuroimaging techni...
    Medical condition: First or second tumour recrurrence/progression of a histological confirmed supratentorial malignant glioma WHO Grade III-IV
    Disease: Version SOC Term Classification Code Term Level
    12.0 10065443 Malignant glioma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004377-99 Sponsor Protocol Number: CSMS995ADE17-RNOP-11/B-01 Start Date*: 2007-04-17
    Sponsor Name:Medizinische Einrichtungen des Bezirks Oberpfalz GmbH
    Full Title: Phase I study of Somatostatin-Analogues as Second Line Treatment in Adult Patients with Recurrent Medulloblastoma (WHO IV)
    Medical condition: patients with medulloblastoma in whom therapy for primary disease (minimum: best possible resection, radiotherapy and one chemotherapy regimen) failed
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004671-37 Sponsor Protocol Number: GEINO-11 Start Date*: 2011-12-19
    Sponsor Name:GRUPO ESPAÑOL DE INVESTIGACION EN NEUROONCOLOGIA
    Full Title: Phase II pilot, prospective, open label, multicenter Clinical Trial, to evaluate the safety and efficacy of PF299804, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with ...
    Medical condition: Patients with recurrent glioblastoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-010390-21 Sponsor Protocol Number: ML21965 Start Date*: 2010-02-10
    Sponsor Name:Roche Pharma AG
    Full Title: A randomized, open-label, multi-center Phase II trial of bevacizumab and radiotherapy fol-lowed by bevacizumab and irinotecan vs. temozolomide and radiotherapy followed by temo-zolomide monotherapy...
    Medical condition: Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005786-14 Sponsor Protocol Number: 7830 Start Date*: 2021-10-13
    Sponsor Name:Hôpitaux Universitaires de Strasbourg B.1.2
    Full Title: A randomized and controlled phase II national protocol in non NF1 pediatric and AYA (Adolescent and Young Adults) patients bearing a wild type BRAF gene newly diagnosed comparing a daily oral MEK i...
    Medical condition: Histologically proven grade 1 glioma/mixed glio-neuronal tumors or pleomorphic xanthoastrocytoma (PXA) confirmed
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Nov 05 12:29:34 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA